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Abstract
Trypanosomes are protozoan parasites that cause diseases in humans and
livestock for which no vaccines are available. Disease eradication requires
sensitive diagnostic tools and efficient treatment strategies. Immunodiagnostics
based on antigen detection are preferable to antibody detection because the latter
cannot differentiate between active infection and cure. Classical monoclonal
antibodies are inaccessible to cryptic epitopes (based on their size-150 kDa), costly
to produce and require cold chain maintenance, a condition that is difficult to
achieve in trypanosomiasis endemic regions, which are mostly rural. Nanobodies
are recombinant, heat-stable, small-sized (15 kDa), antigen-specific, single-
domain, variable fragments derived from heavy chain-only antibodies in camelids.
Because of numerous advantages over classical antibodies, we investigated the
use of nanobodies for the targeting of trypanosome-specific antigens and
diagnostic potential. An alpaca was immunized using lysates of Trypanosoma
evansi. Using phage display and bio-panning techniques, a cross-reactive
nanobody (Nb392) targeting all trypanosome species and isolates tested was
selected. Imunoblotting, immunofluorescence microscopy, immunoprecipitation and
mass spectrometry assays were combined to identify the target recognized. Nb392
targets paraflagellar rod protein (PFR1) of T. evansi, T. brucei, T. congolense and T.
vivax. Two different RNAi mutants with defective PFR assembly (PFR2RNAi and
KIF9BRNAi) were used to confirm its specificity. In conclusion, using a complex
protein mixture for alpaca immunization, we generated a highly specific nanobody
(Nb392) that targets a conserved trypanosome protein, i.e., PFR1 in the flagella of
trypanosomes. Nb392 is an excellent marker for the PFR and can be useful in the
OPEN ACCESS
Citation: Obishakin E, Stijlemans B, Santi-Rocca
J, Vandenberghe I, Devreese B, et al.
(2014) Generation of a Nanobody Targeting the
Paraflagellar Rod Protein of Trypanosomes. PLoS
ONE 9(12): e115893. doi:10.1371/journal.pone.
0115893
Editor: Kevin K. A. Tetteh, London School of
Hygiene and Tropical Medicine, United Kingdom
Received: July 7, 2014
Accepted: November 27, 2014
Published: December 31, 2014
Copyright:  2014 Obishakin et al. This is an
open-access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and repro-
duction in any medium, provided the original author
and source are credited.
Data Availability: The authors confirm that all data
underlying the findings are fully available without
restriction. All relevant data are within the paper
and its Supporting Information files.
Funding: This work was supported by the
European Union/FP7 Nanotryp (FP7-HEALTH
2007-2.3.4-1) and the Fund for Scientific Research
Flanders (FWO). Work at the Institut Pasteur was
funded by a French Government Investissement
d’Avenir program, Laboratoire d’Excellence
‘‘Integrative Biology of Emerging Infectious
Diseases’’ (ANR-10-LABX-62- IBEID), the Institut
Carnot Maladies Infectieuses and the Fondation
pour la Recherche Me´dicale. The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the manu-
script.
Competing Interests: The authors have declared
that no competing interests exist.
PLOS ONE | DOI:10.1371/journal.pone.0115893 December 31, 2014 1 / 17
diagnosis of trypanosomiasis. In addition, as demonstrated, Nb392 can be a useful
research or PFR protein isolation tool.
Introduction
Trypanosomes are a family of haemoflagellates that cause chronic infections in
humans and livestock. Human African Trypanosomiasis (HAT) is caused by
Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense [1]. Animal
African Trypanosomiasis (AAT) known as nagana is mainly caused by
Trypanosoma vivax, Trypanosoma congolense and Trypanosoma brucei brucei [2, 3].
Trypanosoma evansi and Trypanosoma equiperdum cause forms of AAT referred to
as surra and dourine respectively [4, 5]. In animals, trypanosomiasis is usually
characterised by undulating fever and parasiteamia, progressive anaemia, loss of
condition, abortions and immunodeficiencies [6, 7].
As there is no effective vaccine against trypanosomiasis [8], treatment of HAT
and AAT is limited to a few drugs that in turn generate serious side effects and
have recently been facing drug resistance [9]. Early detection and control is the
only way to prevent outbreaks. Hence, there is a need for sensitive and specific
diagnostic measures [10, 11].
Parasitological and serological techniques are currently used for the diagnosis of
trypanosome infections but are limited by their low sensitivity. Antibody detecting
serological tests such as indirect-ELISA, indirect immunofluorescence tests and
card agglutination are also used, however, they lead to largely presumptive
diagnosis because active infections are not verifiable and distinctions between
cured and uncured cases cannot be made. In addition, specificity and sensitivity of
these tests require further evaluation. Recently, research has turned towards
methods for antigen detection [12, 13].
In addition to the conventional IgG antibody, the immune system of camelids
produce heavy-chain antibodies (HCAbs) which are devoid of light chains, lack
CH1 domains in their heavy chain and are capable of antigen recognition [14]. In
camels, 50–80% of immunoglobulins are heavy chain-only antibodies while in
South American camelids (llama, alpaca, guanaco and vicugna) about 10–25%
belong to this group [15]. The antigen binding part of the single domain antibody
can be produced by recombinant expression in bacteria commonly referred to as
Nanobody (Nb). With a dimension of,462.2 nm, a molecular weight of 15 kDa
and high affinity and specificity for their targets, they have the ability to
specifically recognize cryptic epitopes that are not easily accessed by classical
antibodies [15, 16]. In addition, they are resistant to chemical and thermal
denaturation and their low production cost makes them attractive. They are now
being used as crystallization chaperones in solving protein structures [17]. In
addition, nanobody technology has been recently introduced as tools in malaria
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and cancer research [18, 19]. Recently, the use of nanobodies in trypanosome
research has been explored [16, 20, 21].
Compared to monoclonal antibodies in research and immunodiagnostics,
nanobody use is relatively new and promising. Although some nanobodies that
recognize trypanosome antigens have been generated [5], isolation of target
protein antigens out of complex sample mixtures using Nbs has not been shown.
Here, we demonstrate the development of Nb targeting specifically a conserved
protein among various trypanosome species and subsequent isolation and
identification of the target protein out of total trypanosome lysates. We also
present one-step direct nanobody based immunofluorescence labelling for
diagnosis of AAT.
Material and Method
Ethics statement
Approval for animal experiments was obtained from the Animal Ethical
Committee of the Vrije Universiteit Brussel (Ethics committee protocol number
10-220-5).
Trypanosome antigen preparation, alpaca immunisation and
lymphocyte isolation
Total parasite lysates were prepared as described before [5] (S1 Material and
Methods). 100 mg each of five different lysates (T. evansi STIB 816, T. evansi
ITMAS 0101399B, T. evansi itmas 150399B, T. evansi ITMAS 120399C and T.
evansi itmas 150399C) were pooled and used to immunize an alpaca with six
subcutaneous injections at weekly intervals. 500 ml of lysate was added to 500 ml
of Gerbu adjuvant LQ 3000 (GERBU Biotechnik) per injection [17]. Four days
after the last boost, 75 ml of anti-coagulated blood was collected from the alpaca
and lymphocytes were isolated using Lymphoprep (Nycomed) according to the
manufacturer’s instruction. The immunization and blood collection was done by
Alpa-Vet (www.alpa-vet.be). Lymphocytes were separated by gradient centrifu-
gation for 25 minutes at 2,000 rpm using an Eppendorf 5810 centrifuge at room
temperature. 56107 lymphocytes were lysed by adding 1 ml of Trizol in
Eppendorf tubes.
Construction of anti-trypanosome Nb library and selection of
specific antibody fragments (Biopanning)
Library construction was done as described [5, 22]. Briefly, mRNA extracted from
the Trizol pellet was used as a template for RT-PCR to generate a first strand
cDNA using oligo-dT primers. cDNA was used as template to amplify 2 different
products using specific primers CALL001 and CALL002 [22] which yielded the
VH and the VHH containing gene fragments of 900 and 600 bp, respectively. The
600 bp product was excised from 1% agarose gel, used as template for a second
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PCR via nested primers A4short and 38 [5] to amplify the VHH sequence of about
400 bp and restricted with Not I and PstI restriction enzymes (Roche). The PCR
fragments were ligated into the phagemid vector pHEN4 [23] and transformed
into electro-competent E.coli TG1 cells. The Resulting nanobody library was
super-infected with M13K07 helper phages for the expression of nanobodies on
the phages. Biopanning was performed as described [22] by coating ELISA plates
(Nunc) with 1 mg amount of T. evansi STIB per well. Phage enrichment was
achieved by 3 rounds of in vitro selection. Phages were eluted as described [22].
TG1 E. coli cells were infected with the eluted phages, and selected from LB-
ampicillin plates. One hundred viable colonies were randomly picked from each
round of panning and their VHH was expressed as described [22]. The
periplasmic extracts (PE) were obtained through osmotic shock as described [24].
The enrichment of each round of panning was checked by a polyclonal phage
ELISA with anti-M13-HRP antibodies [5]. Each colony PE from round two and
three was tested on PE-ELISA using mouse anti-heamaglutinin antibodies [5] and
further tested on two other lysates (T. evansi 0101399B, T. evansi 150399B) for
cross reactivity.
Expression and purification of antibody fragments for ELISA
testing
The cloned insert that expressed protein recognizing various trypanosome lysates,
was sequenced using the RP or GIII primer [17] and sequences were grouped
based on the differences in their complementarity determining regions (CDRs).
Representatives of each group were recloned into the expression vector pHEN6
using Eco91I (Thermo scientific) and Pst I (Roche) enzymes. The plasmid
constructs were transformed into WK6 E. coli cells and large quantities of His6
tagged recombinant Nb were expressed as described [22] following periplasmic
expression through osmotic shock as described [24]. The PE was initially purified
using 1 ml of HIS-Select Nickel Affinity Gel (Sigma-Aldrich) and elution was
performed with 1 column volume of 0.5 M imidazole repeated 3 times. The
elution was purified on Hiload Superdex-75 (16/600) gel filtration column
(Aktaxpress, GE Healthcare) as described [22]. Solid phase ELISA was performed
by coating of different trypanosome lysates (5 mg/well) on Maxisorb 96 well plates
(Nunc) at 4 C˚ overnight. The ELISA was performed as described [5] using
purified Nb as primary antibody, followed by in-house generated rabbit
polyclonal anti-VHH IgG and a goat anti-rabbit-IgG antibody conjugated to
horseradish peroxidase (Sigma-Aldrich). A non-relevant nanobody (NbBCII10)
[22] was used as negative control for antibody detection while a non-relevant
protein, Bovine serum albumin (BSA) was used as negative control for lysate
coatings.
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Flow cytometry and Immunofluorescence Assay (IFA)
From the result of ELISA using purified nanobodies, Nb392 was selected and
labeled directly by conjugation with ALEXA Fluor 488 (Molecular Probes)
according to the manufacturer’s instructions. The labeled Nb392 was used for
flow cytometry and immunofluorescence assays on purified, fixed and
permeabilised (S1 Material and Methods) bloodstream forms of T. evansi STIB
816, T. brucei brucei AnTat1.1, T. congolense Tc13 and T. vivax IL700 strains.
ALEXA labelled NbBCII10 was used as negative control.
Western blotting
To identify the target of Nb392 in the flagella, western blots were performed on
total lysates as described [16] using Nb392 probed with in-house generated rabbit
polyclonal anti-VHH IgG and a goat anti-rabbit-IgG antibody conjugated to
horseradish peroxidase (Sigma-Aldrich). For phenotypic confirmation that Nb392
targets PFR1/2, IFA and immunoblotting were conducted on RNAi mutants of
PFR protein, PFR2RNAi [25] and KIF9BRNAi [26] mutant (procyclic) parasites
using same protocols as performed on parasites and lysates above (S1 Material
and Methods) Anti-ALBA antibodies were used as loading controls [27].
Antigen identification by immunoprecipitation of flagella extracts
and mass spectrometry
Flagella extraction was performed on T. evansi STIB816 parasites using Triton X-
100 as described [28] (S1 Material and Methods, S1 Fig.). Nb392 was immobilized
covalently on N-hydroxysuccinimide (NHS) activated dry agarose resin according
to the manufacturer’s instructions (Thermo scientific pierce) overnight at 4 C˚.
After quenching the unbound sites with 1.0 M Tris-HCl pH 7.4, flagella extracts
was added at room temperature for 3 hours, washed with PBS, acidic elution was
performed with 0.2 M glycine-HCl, pH 2.5 according to the manufacturer’s
instructions. 1–3 mg of the eluted protein was resolved by SDS-PAGE using a
12.5% premade polyacrylamide gel, later stained with 0.1% commassie Brilliant
Blue R-250 in 40% Methanol for 1–2 minutes, followed by washing with 50%
methanol. The resulting two bands were excised separately for mass spectrometry.
Maldi-MS of gel bands
The protein bands were exiced from gel and digested with trypsin in
ammoniumbicarbonate. Digestion and peptide extraction were performed
according to standard protocols [29] (S1 Material and Methods). Sample Ms and
tandem Ms spectra were acquired on a 4800 Proteomics Analyzer. Data analyses
were performed using 4000 Series Explorer and Data explorer software. Protein
identification was obtained by applying the Mascot Search Engine against the
Swissprot database, taxonomy eukaryotes and implying decoy database searches.
The parameters were set to mono-isotopic mass values using peptide charge +1
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and the peptide mass tolerance was set to 200 ppm, with a maximum of missed
cleavages of two. Methionine oxidation was set as a Variable modification; the
significance tolerance threshold was set below 0.05. Protein identification was
derived from peptide fragmentation spectra using the fragmentation ion
simulator of the Data explorer software.
Statistical Analysis
FACS data were analysed using Flowjo software and ELISA data were translated
into graphical representations using Prism software (GraphPad Prismv.4.0,
GraphPad Software Inc. San Diego, CA). ELISA experiments were performed
minimum of three times with lysates coated in triplicates. Data are presented as
mean values ¡ SD. Student’s t test was used to compare means. If p . 0.05,
differences were considered significant. Asterisks were used to indicate the degrees
of significance (*P,0.05, **P,0.01, ***P,0.001).
Results
Anti-trypanosome Nb library construction and selection of specific
nanobody fragments
Gene fragments of heavy chain antibodies from the immunized alpaca were
cloned into the phagemid vector pHEN4 and used to construct a Nb library
containing ,2.266107 individuals by transforming TG1 E.coli cells. Colony PCR
showed ,80% of the clones contained the expected insert size (,700 bp).
Compared binding capacity of phages from three rounds showed the highest
ELISA OD readings at the third round, suggesting a progressive enrichment.
Furthermore, ELISA tests with PE extracts of individual clones revealed that 39
colonies out of 49 reacted on 2 different T. evansi lysate (data not shown). VHH
genes of these clones were cloned into the pHEN6 vector and sequenced for
confirmation. Clones were transformed into WK6 E. coli cells for large-scale
periplasmic expression. Amino acid sequence analysis of the binders showed five
nanobody groups but three distinct families based on CDR3 differences (Fig. 1). A
representative of each family (Nb211, Nb358, and Nb392) was expressed and
purified. Out of the 3 selected Nbs, Nb392 showed the highest OD value in an
ELISA on 5 strains of T. evansi tested (data not shown) and therefore was selected
for further analysis.
Nb392 detects an intraflagellar antigen
In ELISA, BSA protein was coated on ELISA plate as negative control antigen.
Using Nb392 for detection, the mean value of OD of the BSA coated wells is 0.083
+/2 0.012, which is considered to be equal background level (data not shown). A
non-relevant nanobody (NbBCII10) was used as a negative control antibody for
all the parasite species as well. When compared, the results show that the signals
obtained using Nb392 on T. evansi STIB816, T. evansi itmas 0101399B, T. evansi
Nanobody Targeting Trypanosome PFR Protein
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itmas 150399B, and T. evansi itmas 150399C were significant. In contrast, Nb392
signal on T. congolense and T. vivax coating gave similar results as those obtained
with the irrelevant control NbBCII10 (Fig. 2). By flow cytometry, ALEXA-488
labeled Nb392 showed no signals on live cells but bound fixed and permeabilised
T. evansi parasites. Similarly, fixed and permeabilised T. brucei, T. congolense and
T. vivax parasites showed positive signals using labeled Nb392 by flow cytometry
(Fig. 3A). These results were confirmed on direct immunofluorescence assay
using ALEXA-labeled Nb392. While live parasites were completely negative, fixed
and permeabilised T. evansi, T. brucei, T. vivax and T. congolense parasites showed
bright staining only in the flagellum (Fig. 3B). Results of both flow cytometry and
direct IFA indicate that Nb392 target is localized within the flagellum.
Fig. 1. Sequence alignment of deduced amino acid. Sequences of the different cross-reactive nanobodies
highlighting the framework (FR) and complementarity determining region (CDR) sequences. CDR sequences
are highlighted in blue, red and green (corresponding to different families), while FR differences are marked in
yellow. The guidelines of the international Immunogenetics information system of numbering are used (http:/
imgt.cines.fr).
doi:10.1371/journal.pone.0115893.g001
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Identification of the Nb392 target protein
To determine the size of the specific protein recognized by Nb392, immuno-
blotting was initially performed on parasite lysates. Two close but distinct bands
of approximately 70 and 73 kDa were consistently detected. Next, immunopre-
cipitation was performed by capturing the target protein from flagella crude
extracts through the covalent immobilization of Nb392 on NHS activated dry
agarose resin. Eluted fractions were resolved by SDS-PAGE. Two protein bands
similar to what was observed by western blotting appeared on the gel when stained
with Commassie blue. The two bands designated 1 (upper) and 2 (lower) were
analyzed via MS. The mass spectra of the tryptic peptides (S2A and S2B Figs.) of
protein samples all match with tryptic peptides derived of the 73 kDa paraflagellar
rod protein 1 (PFR1) protein (Table 1).
Fig. 2. Solid-phase ELISA result. Coating 5 mg/well of soluble protein of parasite lysates (T. evansi strains, T. congolense and T. vivax) and subsequent
recognition by Nb392 and non-relevant nanobody (NbBCII10) as negative control. In each of three separate experiments, lysates were plated in triplicates
and detected with Nb392 (shaded boxes) or NbBCII10 (unshaded boxes). Data presented are mean values of three wells (¡SD). The mean values of
negative control wells are compared to the mean values of corresponding test wells coated with lysates of T. evansi strains, T. vivax and T. congolense,
*P,0.05, **P,0.01, ***P,0.001. Results shown are representative of three independent experiments.
doi:10.1371/journal.pone.0115893.g002
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Confirmation of Nb392 reactivity using trypanosome PFR mutants
The PFR2RNAi T. brucei procyclic strain expresses double stranded RNA of the
PFR2 gene under the control of a tetracycline inducible promoter [25]. When
RNAi is activated, PFR2 is not expressed and only a rudimentary PFR structure is
assembled that nevertheless still contains PFR1 [25, 30]. Immunoblotting with
Nb392 revealed 85% reduction in PFR signal intensity 2 days after RNAi
induction (Fig. 4). Double immunofluorescence was performed using Nb392 and
the monoclonal antibody mAb25 [31] as an independent axoneme marker. While
the axoneme marker exhibited normal flagella staining, Nb392 only showed a very
faint staining, indicating the presence of PFR1 (Fig. 5A–C).
KIF9B is a flagellar kinesin essential for correct assembly of the PFR. When
absent, trypanosomes assemble flagella of normal length but with defective PFR
distribution [26]. To further confirm if Nb392 binds to PFR proteins,
immunoblotting was performed using the KIF9BRNAi mutant [26]. When KIF9B
was silenced, a 67% reduction in both PFR bands’ intensity was detected by
Fig. 3. A. Flowcytometric profiles showing binding of ALEXA-labeled Nb392 to fixed and permeabilised trypanosomes. Fixed and permeabilised
cells: unstained (red) and stained (blue) T. evansi STIB 816, stained T. evansi Itmas 010399b (light green), stained T. evansi Itmas 120399b (dark green),
stained T. evansi Itmas 150399b (orange); B) Unstained live T. brucei AnTat1.1 (red), fixed and permeabilised T. brucei AnTat1.1 unstained (blue), stained
(green), stained with control NbBCII 10 (orange); C) Fixed and permeabilised T. vivax IL700 unstained (red) or stained (blue); D) Fixed and permeabilised T.
congolense Tc13 unstained (red) or stained (blue). B. Direct Immunofluorescense assay of fixed and permeabilised trypanosomes. Fixed and
permeabilised trypanosomes incubated with Alexa 488- labeled Nb392 (green) and with DAPI (blue) staining nuclear and mitochondrial DNA. A) T. evansi
STIB 816; B) T. brucei; C) T. congolense Tc13; D) T. vivax IL700. Magnification; X1000.
doi:10.1371/journal.pone.0115893.g003
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Table 1. List of peptide masses from mass spectra of upper and lower bands and their respective sequence matches with the positions in the genome of T.
brucei.
Peptide masses (Da) in upper protein
band
Peptide masses (Da) in lower protein
band sequence position
1316,4698 1316,4698 (R)IEEIDREEK(R) 346(7)–356(7)
1301,1904 1301,1904 AEELVAAVDVGTK 57–69
- 1193,4562 LGTERFDEVK 336–345
1049,3983 1049,3983 ELYRPEDK 93–100
1664,7115 - VEYSQFLEVASQHK 359–372
- 1707,5337 CTGLVEELVSEGCAAVK 388–404
- 1585,5837 LDVHKEHLEYFR 419–430
- 1566,4888 TSQDLAALRLDVHK 410–423
1876,9585 - MVEYRSHLTKQEEVK 539–553
1841,9967 - SQLDATQLAQVPTQTLK 149–165
1349,7171 1349,7171 LGTERFDEVKR 336–346
1260,731 1260,731 LIDLIQDKFR 227–236
1214,6851 1214,6851 IAAEREEIKR 554–563
1141,6436 1141,6436 VLQDLRQNR 112–120
doi:10.1371/journal.pone.0115893.t001
Fig. 4. Western blot analysis on wild type and mutant parasites probed with Nb392 and anti-ALBA as
loading control. From left to right upper panel: WT T. brucei procyclics, PFR2RNAi uninduced, PFR2RNAi 2-
day induction, KIF9BRNAi uninduced, KIF9BRNAi 4-day induction T. evansi blood form, T. brucei WT blood
form, T. brucei procyclics WT calibration with 26106, 16106, 56105, 2.56105 and 1.256105 parasites.
Lower panel: Anti-ALBA antibody used as loading control. Values on the left are given in kilodaltons.
doi:10.1371/journal.pone.0115893.g004
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imunoblotting using Nb392, as compared to wild type parasites (Fig. 4). Likewise,
IFA revealed discontinuous Nb392 signal all along the length of the flagellum
(Fig. 5D–E). Collectively, results demonstrate that the antigen detected by Nb392
behaves as expected for PFR1 in two distinct mutant contexts.
Discussion
In this study, we produced a nanobody termed Nb392 and demonstrated it
recognises PFR1. Generated originally against a T. evansi sample, Nb932 was
shown to also recognize PFR homologues in T. brucei, T. congolense and T. vivax,
indicating its potential use for the development of diagnostic tools for AAT.
Moreover, a novel nanobody based immunoprecipitation is reported, permitting
the isolation of the target protein from a complex mixture of trypanosome soluble
extract.
Development of sensitive diagnostic methods readily available on the field
remains a priority in trypanosomiasis control [32]. Microscopic examination is
the most common diagnostic measure on the field but it lacks sensitivity.
Antigenic variation and low antibody turnover in active or chronic infections
make antigen detection and capturing methods to be preferable over antibody
Fig. 5. Immunofluorescence assay on T. brucei procyclic cells showing reactivity of Nb392 in two PFR
mutants. Horizontal rows from top to bottom: Wild type (A) PFR2RNAi uninduced (B), PFR2RNAi induced (C),
KIF9BRNAi uninduced (D), KIF9BRNAi induced (E), Vertical columns from left to right: combined phase-contrast
DAPI, mAb25 and Nb392 images (left), DAPI images (middle left), mAb25 (middle right), Nb392 (right). Scale
bar: 5 mm.
doi:10.1371/journal.pone.0115893.g005
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detection methods. Moreover, a test of cure cannot be performed as antibodies
that recognize diagnostic antigen can remain in the serum after treatment [12, 33].
However, classic mouse monoclonal antibodies face biological (inaccessibility to
cryptic epitopes) and practical (high cost of production, necessity for a cold chain
incompatible with conditions encountered in the field) issues, prompting a search
for antibodies of high affinity, high thermo-stability, access to cryptic epitopes and
low production costs. To improve detection and antigen capturing in
trypanosome research, we investigated the alternative use of nanobodies.
Antibody selection for antigen capturing is usually done by immunizing an
animal with a known ‘preferred’ protein target [17] or with complex protein
mixtures such as total lysates [34]. So far, using specific proteins has not been
successful in developing antigen-specific tests for trypanosomiasis. We therefore,
preferred an inverse proteomics approach. Immunizing with complex protein
mixtures is beneficial: first, antibodies are produced against mixed antigen as in
natural infection. Second, purified or recombinant antigen is not essential for
immunization and screening. Third, antibodies against post-translational
modified variants can be elicited. Fourth, selection of an antibody recognizing a
dominant antigen in a properly folded native form is favoured.
Here, an alpaca was immunized with whole soluble extract of T. evansi STIB816
parasites. Nanobody gene fragments were selected by panning the generated VHH
library on the same antigen as bait and tested for cross-reactivity to other
trypanosome species and strains. In flow cytometry analysis and IFA, Nb392 was
shown to be cross-reactive to all T. evansi tested and to T. brucei, T. vivax and T.
congolense species, exclusively binding to the flagellum on IFA. In solid phase
ELISA, Nb392 binds total lysates of T. evansi STIB 816 and all other T. evansi
strains while also recognizing T. brucei AnTat 1.1 strain. This can be attributed to
close relatedness of T. evansi and T. brucei species [35]. The signals obtained by
using Nb392 on T. evansi strains were significantly different from the signals
obtained using an irrelevant nanobody (NbBCII10) while signals using Nb392 on
T. congolense and T. vivax protein extracts were not significantly different from the
signals obtained by using the irrelevant nanobody on the same lysates, hence
considered negative. This indicates that the target is less conserved in these species
when compared to T. evansi and T. brucei species. Furthermore, ELISA was
performed using total lysates, this probably resulted in competitions between the
target protein and numerous other proteins while IFA was performed on intact,
fixed and permeabilised parasites, this may have contributed to the weak signals
observed in ELISA using T. vivax and T. congolense. Moreover, IFA and flow
cytometry could both be more visually sensitive than ELISA.
Considering the IFA flagella signals and imunoblotting showing that Nb392
recognizes two trypanosome flagella proteins between 70–73 kDa, Nb392 was
used for immunoprecipitation of flagella proteins. Mass spectra of all the tryptic
peptides of the two protein bands captured by Nb392 matched with tryptic
peptides of PFR1 proteins, confirming that in natural conditions used for
immunoprecipitation and IFA, Nb392 binds to PFR1. The lower band could result
from subtle proteolytic cleavage of PFR1 or due to sensitivity of PFR proteins to
Nanobody Targeting Trypanosome PFR Protein
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oxidation or reduction, shifting their migrating pattern as previously observed
[36].
To confirm that Nb392 targets PFR, we used both PFR2RNAi and KIF9BRNAi
mutant parasites. In PFR2RNAi mutants, Nb392 showed a much-reduced signal, in
agreement with the presence of a rudimentary PFR structure composed of PFR1
[30], hence indicating PFR1 as a primary target of Nb392. Likewise, staining of the
KIFB9RNAi parasite revealed a discontinuous signal, as observed for several PFR
proteins. Second, imunoblotting showed significant reduction in the amount of
both PFR1 and PFR2 band intensities in KIFB9RNAi and PFR2RNAi mutants when
compared to the WT. In imunoblotting of mutants, the recognition of upper
(PFR1) protein band further confirms the targeting of PFR1 by Nb392 in a
reduced condition. Notably, PFR2 band was recognized, indicating the presence of
a residual PFR2 protein in PFR2RNAi mutants and also suggesting that Nb392 can
recognize PFR2 only in reduced conditions corroborating PFR1/PFR2 similarity
[37, 38].
The trypanosome flagellum contains up to 600 proteins [39–41]. Within the
flagellum, the PFR is a complex, three-dimensional structure that runs alongside
the microtubular axoneme [28, 42] and is vital for trypanosome motility [43] and
survival in vivo [44]. The PFR alone contains more than 30 proteins [45],
including PFR1 and PFR2 which are most abundant and encoded by a cluster of at
least 5 identical genes each [36, 37]. The coding sequences of PFR1 is 67%
identical to PFR2 [37]. Since more PFR are being discovered [41] highly specific,
consistent and easy-to-produce markers are needed to optimize investigation into
the PFR. Our results demonstrate that Nb392 is an excellent marker for the PFR.
Furthermore, despite the PFR complexity, the successful isolation of PFR1 protein
from an intrinsic protein mixture demonstrates the specificity of Nb392 for PFR
protein. This will be useful in purification of this protein for vaccination,
diagnosis and general research purposes. Furthermore, bloodstream and procyclic
forms were used for flow cytometry and immunofluorescence experiments
showing that Nb392 likely works on all parasite stages. Considering our
immunization protocol, our result reiterates the immunodominance and
abundance of PFR1 and PFR2 [46].
Finally, PFR proteins in T. cruzi were shown to be attractive targets for
generating protective immunity against trypanosomes [47, 48]. Due to its
immunogenic and abundant nature, as well as its high conservation in many
parasitic species, PFR could be an ideal diagnostic target. Phylogenetic analysis of
PFR sequences of kinetoplastids reveals closer relatedness among the genus
Trypanosoma (T. brucei, T. congolense and T. vivax) while highlighting a distant
relatedness to T. cruzi [49].
Combined, we demonstrate a novel immunoprecipitation capability of
nanobodies by isolating PFR proteins from trypanosome lysate using Nb392.
Being a recombinant antibody fragment, it can easily be adapted to various
tracking or detection devices such as the lateral flow dipstick. It can also serve as
an interesting alternative to already existing mouse anti-PFR monoclonal
antibodies [38] for multiple staining by IFA if biotinylated or labelled with
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fluorophore. However, the negative ELISA signals obtained on T. congolense and
T. vivax lysates limit the use of Nb392 as a species cross reactive antigen-ELISA
antibody. Hence, work should be done to optimize the amplification of the signals
or improve the avidity of Nb392 to these strains. As such, possibility of
biotinylated or bivalent Nb392 constructs should be explored. Apart from lysates,
serum antigen detection should be validated. Compared to conventional
monoclonal antibodies, Nbs are heat stable, the development of Nb392 opens a
new dimension and shows the potentials of the use of nanobody technology for
diagnostic, crystallization and other protein research purposes in trypanosomes
and other disease agents. With respect to the use of Nb392 for diagnosis of
trypanosomiasis, the fact that Nb392 cannot distinguish between PFR proteins of
different trypanosome species is less important in AAT treatment. This is because
the treatment of AAT is done with similar drugs irrespective of the species
responsible hence, the cross- reactivity of Nb392 may even be considered an
advantage.
Supporting Information
S1 Fig. Flagellum purification. Sample of purified flagella from T. evansi STIB
816 viewed by bright-field microscopy. Magnification X1000.
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